Literature DB >> 7506438

Effect of ifosfamide metabolites on sodium-dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture.

M Mohrmann1, A Pauli, H Walkenhorst, B Schönfeld, M Brandis.   

Abstract

Ifosfamide (IF) is an alkylating cytostatic drug with urotoxic (hemorrhagic cystitis) and nephrotoxic side effects. Several cases of Fanconi syndrome in children following therapy with IF were reported. Little information is available concerning the pathomechanisms of transport inhibition by IF. We used a permanent renal epithelial cell line with proximal tubular characteristics (LLC-PK1) in order to investigate the effects of IF and some of its major metabolites (4-OH-IF, chloracetaldehyde, and acrolein). LLC-PK1 cells were used in a confluent state. Sodium-dependent and sodium-independent fluxes of 32PO4 were determined by standard techniques. Activities of marker enzymes of apical and basolateral membranes, of mitochondria, and of endoplasmic reticulum were determined in cell homogenates. IF induces a moderate stimulation of PO4 transport. 4-OH-IF also has a stimulatory effect on transport at low concentrations (up to 200 mumol/l) and with short incubation (2h), while a 24-hour exposure of cells to 100 mumol/l of 4-OH-IF has an inhibitory effect of PO4 transport. Concentrations of 4-OH-IF which inhibit transport also reduce the activity of Na(+)-K(+)-ATPase. Chloracetaldehyde, like 4-OH-IF, induces a biphasic response of PO4 transport with stimulation in the low concentration range (up to 75 mumol/l) and inhibition at higher concentrations. Chloracetaldehyde reduces the activity of succinate-cytochrome c oxidoreductase, suggesting that a defect in ATP generation might play a role in the pathogenesis of Fanconi syndrome induced by IF. Acrolein strongly damages monolayers and reduces sodium-dependent transport of PO4 to very low levels at 150 mumol/l. It reduces the activities of both Na(+)-K+ ATPase and succinate-cytochrome c oxidoreductase. Acrolein also is the only metabolite with a moderate effect on alkaline phosphatase. We conclude that sodium-dependent transport of PO4 is highly sensitive to IF metabolites. In addition to direct toxic effects of IF metabolites on transport proteins within the apical plasma membrane, damage to mitochondrial enzymes and to Na(+)-K+ ATPase which generates the electrochemical gradients for secondary active PO4 transport may play an important role in the pathogenesis of Fanconi syndrome induced by IF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506438     DOI: 10.1159/000173775

Source DB:  PubMed          Journal:  Ren Physiol Biochem        ISSN: 1011-6524


  4 in total

1.  Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.

Authors:  Diane M Calinski; Haoming Zhang; Susan Ludeman; M Eileen Dolan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2015-05-01       Impact factor: 3.922

2.  Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Authors:  Jeannine S McCune; Tao Wang; Khalid Bo-Subait; Mahmoud Aljurf; Amer Beitinjaneh; Joseph Bubalo; Jean-Yves Cahn; Jan Cerny; Saurabh Chhabra; Aaron Cumpston; L Lee Dupuis; Hillard M Lazarus; David I Marks; Richard T Maziarz; Maxim Norkin; Tim Prestidge; Shin Mineishi; Maxwell M Krem; Marcelo Pasquini; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-11       Impact factor: 5.742

3.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

4.  Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.

Authors:  M Mohrmann; S Ansorge; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.